Literature DB >> 10837079

DNA vaccines: immunology, application, and optimization*.

S Gurunathan1, D M Klinman, R A Seder.   

Abstract

The development and widespread use of vaccines against infectious agents have been a great triumph of medical science. One reason for the success of currently available vaccines is that they are capable of inducing long-lived antibody responses, which are the principal agents of immune protection against most viruses and bacteria. Despite these successes, vaccination against intracellular organisms that require cell-mediated immunity, such as the agents of tuberculosis, malaria, leishmaniasis, and human immunodeficiency virus infection, are either not available or not uniformly effective. Owing to the substantial morbidity and mortality associated with these diseases worldwide, an understanding of the mechanisms involved in generating long-lived cellular immune responses has tremendous practical importance. For these reasons, a new form of vaccination, using DNA that contains the gene for the antigen of interest, is under intensive investigation, because it can engender both humoral and cellular immune responses. This review focuses on the mechanisms by which DNA vaccines elicit immune responses. In addition, a list of potential applications in a variety of preclinical models is provided.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837079     DOI: 10.1146/annurev.immunol.18.1.927

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  287 in total

1.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

3.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

6.  Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

7.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 8.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

9.  The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance.

Authors:  Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Jina Kazzaz; Elawati Soenawan; Derek T O'Hagan
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

10.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.